The estimated Net Worth of Andreas Muehler is at least $2.57 Million dollars as of 12 May 2022. Andreas Muehler owns over 3,500 units of Immunic stock worth over $452,939 and over the last 4 years he sold IMUX stock worth over $0. In addition, he makes $2,118,070 as Chief Medical Officer at Immunic.
Andreas has made over 2 trades of the Immunic stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 3,500 units of IMUX stock worth $17,850 on 12 May 2022.
The largest trade he's ever made was buying 10,006 units of Immunic stock on 2 March 2021 worth over $155,493. On average, Andreas trades about 1,929 units every 62 days since 2021. As of 12 May 2022 he still owns at least 297,986 units of Immunic stock.
You can see the complete history of Andreas Muehler stock trades at the bottom of the page.
Dr. Andreas Muehler M.D. serves as Chief Medical Officer of the Company. Dr. Muehler has worked within the pharmaceutical industry since 1992, mostly in the U.S., with leadership positions in preclinical and clinical development, business development and licensing and marketing. Since 2003, Dr. Muehler developed and managed multiple medical companies in the U.S. Among them were 3TP LLC d/b/a CAD Sciences (White Plains, NY), a medical software company developing an imaging solution for early detection of breast and prostate cancer, and Cellectar Inc. (Madison, WI), a biotech company developing new cancer therapeutics and cancer imaging agents. Dr. Muehler was also President CEO of MicroMRI Inc. (Langhorne, PA), a medical device company developing solutions for improved osteoporosis diagnosis and therapy monitoring based on bone micro-architecture. He has been on the board of directors of multiple small medical technology companies. After moving to Munich in 2009, Dr. Muehler became managing director of the small healthcare private equity fund Palladius Healthcare GmbH (Munich, Germany), which acquired distressed medical technology companies. Thereafter, Dr. Muehler worked as interim manager and independent senior medical consultant with multiple assignments for clients in the pharmaceutical and medical device industries.
As the Chief Medical Officer of Immunic, the total compensation of Andreas Muehler at Immunic is $2,118,070. There are 1 executives at Immunic getting paid more, with Daniel Vitt having the highest compensation of $2,383,930.
Andreas Muehler is 54, he's been the Chief Medical Officer of Immunic since 2019. There are 3 older and 12 younger executives at Immunic. The oldest executive at Immunic, Inc. is Tamar Howson, 72, who is the Independent Director.
Andreas's mailing address filed with the SEC is 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK CITY, NY, 10036.
Over the last 5 years, insiders at Immunic have traded over $174,861 worth of Immunic stock and bought 176,506 units worth $558,583 . The most active insiders traders include Barclay A Phillips, Joerg Neermann, and Duane Nash. On average, Immunic executives and independent directors trade stock every 74 days with the average trade being worth of $15,244. The most recent stock trade was executed by Daniel Vitt on 26 February 2024, trading 14,000 units of IMUX stock currently worth $18,340.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Immunic executives and other stock owners filed with the SEC include: